MEDCAC Review Of Anti-VEGF Drugs Rescheduled To March 21, 2012
This article was originally published in The Pink Sheet Daily
Panel will consider benefits of Avastin, Lucentis in diabetic macular edema, addressing questions released by CMS.
You may also be interested in...
The Institute for Clinical and Economic Review conducted a technology assessment for anti-VEGF agents in diabetic macular edema for CMS in preparation for an upcoming MedCAC review.
Eylea manufacturer Regeneron says the new treatment for wet AMD is being reimbursed by all regional Medicare claims contractors.
Targeted drugs indicated for use with companion diagnostics raise the kind of reimbursement concerns that may make them eligible topics for a Medicare national coverage determination, Steve Phurrough, former director of the Centers for Medicare and Medicaid Services coverage and analysis group, suggests.